Omega Therapeutics, Inc.
OMGADelisted Mar 20, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850838
Omega Therapeutics, Inc. was delisted on Mar 20, 2025; its insiders filed their last Form 4 on Dec 5, 2024; 53 institutions reported holding it in 13F filings for Q4 2024, worth $35.3M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 53
- Q4 2024, 0 vs. previous quarter
- 13F value
- $35.3M
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $3.09M
- No comparable prior period
- Net income, FY2023
- -$97.4M
- No comparable prior period
- Free cash flow, FY2023
- -$94.4M
- No comparable prior period
- Revenue, Q3 FY2024
- $2.61M
- +214.3% year over year
Revenue flow, FY2023
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2023: $97.4M (3148.9% of revenue).
Superinvestors holding OMGA, Q4 2024
Go to the superinvestors tabNo superinvestor reported holding OMGA at the end of Q4 2024.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Omega Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2023 (view filing) | Jun 2 | 3 days | Young Richard ADirector | SSale | −5.00K | $8.00 | −$40.0K | −0.7%739.1K after | |
| May 3, 2023 (view filing) | May 1 | 2 days | Young Richard ADirector | SSale | −5.00K | $8.00 | −$40.0K | −0.7%744.1K after | 10b5-1 |
| Apr 10, 2023 (view filing) | Apr 6 | 4 days | Young Richard ADirector | SSale | −5.00K | $8.00 | −$40.0K | −0.7%749.1K after | 10b5-1 |
| Mar 20, 2023 (view filing) | Mar 17 | 3 days | Young Richard ADirector | SSale | −10.0K | $8.00 | −$80.0K | −1.3%754.1K after | |
| Feb 27, 2023 (view filing)5:20 PM ET | Feb 27 | Same day | Afeyan Noubar and 3 othersDirector, 10% Owner | PPurchase | +3.32M | $5.78 | +$19.2M | New position1.33M after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 10 | 1 day | Young Richard ADirector | SSale | −20.0K | $8.00 | −$160.0K | −2.6%764.1K after | |
| Sep 15, 2022 (view filing) | Sep 14 | 1 day | Young Richard ADirector | SSale | −10.0K | $8.00 | −$80.0K | −1.3%784.1K after | |
| Aug 5, 2021 (view filing)5:43 PM ET | Aug 3 | 2 days | Flagship Pioneering, LLC and 5 others10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | +266.7%1.62M after | 3 lotsDuplicate filing |
| Aug 5, 2021 (view filing)5:41 PM ET | Aug 3 | 2 days | Afeyan Noubar and 9 othersDirector, 10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | +266.7%1.62M after | 3 lots |
| Aug 3, 2021 (view filing)5:16 PM ET | Jul 30-Aug 3 | 4 days | Artal Group S.A. and 8 others10% Owner | PPurchase | +950.0K | $16.93 | +$16.1M | +71.8%2.27M after | 2 lots |
Top 10 13F holders, Q4 2024
See all 53 holdersThe largest institutional positions in Omega Therapeutics, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 29,225,579 | $21.8M | 6.52% | 00.0% | Unchanged |
| FMR LLC | 5,924,846 | $4.42M | 0.00% | −137,258−2.3% | Reduced |
| HarbourVest Partners LLC | 3,512,110 | $2.62M | 1.29% | 00.0% | Unchanged |
| State of Wisconsin Investment Board | 1,857,265 | $1.38M | 0.00% | 00.0% | Unchanged |
| Siren, L.L.C. | 1,323,530 | $986.8K | 0.04% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,097,106 | $818.4K | 0.00% | −17,625−1.6% | Reduced |
| Blue Owl Capital Holdings LP | 1,055,882 | $787.3K | 0.19% | 00.0% | Unchanged |
| 683 Capital Management, LLC | 600,000 | $447.4K | 0.04% | 00.0% | Unchanged |
| Millennium Management LLC | 520,898 | $388.4K | 0.00% | −14,718−2.7% | Reduced |
| 72 Investment Holdings, LLC | 352,941 | $263.2K | 0.54% | 00.0% | Unchanged |
Holders of 5% or more of OMGA
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Omega Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flagship V VentureLabs Rx Fund, L.P. | 13D/A | 52.80%29.2M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |
| Flagship Ventures Fund V, L.P. | 13D/A | 52.80%29.2M shares | – | Aug 6, 20213 filings | Dec 31, 2024 | SEC |